Hari Anant Deshpande MD

Endocrine Cancer, Genitourinary Oncology, Head & Neck Cancer, Sarcoma

Associate Professor, Comprehensive Cancer Center, Yale University School of Medicine

20 York StNew Haven, CT 06510
Phone+1 203-200-4822
Fax+1 203-200-2099

Dr. Deshpande is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Deshpande's full profile Already have an account?

Summary

Dr. Hari Deshpande is an oncologist based in New Haven, CT, with subspecialties in endocrine cancer, genitourinary oncology, head and neck cancer, and sarcoma. His medical training includes an internship, residency, and fellowship at Jacobi Medical Center/Albert Einstein College of Medicine, following his graduation from the University of Leeds School of Medicine in 1991. Dr. Deshpande has experience in neuro-oncology and various types of cancer such as squamous cell cancer of the bladder, thyroid, and parathyroid cancers. He has contributed to medical literature with publications in prominent journals like The New England Journal of Medicine and Cancer. His clinical trial involvement includes research on treatments for head and neck squamous cell carcinoma and desmoid tumors. Dr. Deshpande has received recognition, including the David Fischer Teaching Award from Yale Cancer Center.

Education & Training

Jacobi Medical Center/Albert Einstein College of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1998
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1993 - 1995
Jacobi Medical Center/Albert Einstein College of MedicineInternship, Internal Medicine, 1992 - 1993
University of Leeds School of MedicineClass of 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2001 - 2027
NV State Medical License 2000 - 2003
NY State Medical License 2001 - 2003
AZ State Medical License 1998 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
COMPLETED
PHASE2
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
COMPLETED
PHASE1
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.
Alice P Chen, Christina L Rosenberger, Nancy Moore, Jared C Foster, Abdul Rafeh Naqash
Journal of Clinical Oncology. 2026-06-01
Trends in metastatic thyroid cancer survival from 1992 to 2022: a SEER database analysis.
Ashwin Govindan, Philippos Apolinario Costa, Richard Feinn, Hari Deshpande
Endocrine Oncology. 2026-01-01
1 citations
Twenty-five years without progress: The enduring challenge of soft tissue sarcomas.
Nicole J Hardy, Khaoula Ben Haj Frej, Rachel Nkansah, Kelly Olino, Hari Deshpande
Cancer. 2025-06-01

Lectures

Establishment of a medical student elective on the oncology consult service using the seven principles of teaching.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Yale Cancer Center Shares Five Things You Need to Know About Sarcoma, a Rare CancerJuly 7th, 2021
New Haven Company's 'Orphan Drug' May Aid Fight Against Rare CancerFebruary 8th, 2021
Connecticut Gets Slight Boost in Vaccine Supply, but Distributors Say They Need More DosesJanuary 28th, 2021